日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The combination of zalfermin and semaglutide has additive therapeutic effects in a diet-induced obese and biopsy-confirmed mouse model of MASH

在饮食诱导的肥胖且经活检证实的MASH小鼠模型中,扎弗明和索玛鲁肽联合用药具有叠加的治疗效果。

Jenny Norlin ,Maria Dermit ,Nikos Sidiropoulos ,Elisabeth D Galsgaard ,Henrik H Hansen ,Michael Feigh ,Sanne S Veidal ,Markus Latta ,Emma Henriksson ,Birgitte Andersen

Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients

在DIO和经活检证实的NASH小鼠模型中对长效GLP1R/GCGR激动剂的评估表明,GLP-1/胰高血糖素激动剂在NASH患者中具有有益作用。

Thomas Monfeuga ,Jenny Norlin ,Anne Bugge ,Elisabeth D Gaalsgaard ,Cesar A Prada-Medina ,Markus Latta ,Sanne S Veidal ,Pia S Petersen ,Michael Feigh ,Dorte Holst

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

在GAN饮食诱导的肥胖且经活检证实患有NASH的小鼠模型中,索玛鲁肽、拉尼菲布诺和饮食干预具有保肝作用。

Mathias B Møllerhøj ,Sanne S Veidal ,Kirstine Tølbøl Thrane ,Denise Oró ,Agnete Overgaard ,Casper Gravesen Salinas ,Martin Rønn Madsen ,Larissa Pfisterer ,Mogens Vyberg ,Eric Simon ,Andre Broermann ,Niels Vrang ,Jacob Jelsing ,Michael Feigh ,Henrik H Hansen

Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis

在非酒精性脂肪性肝炎和纤维化小鼠模型中,激活甲状腺激素受体-β 可改善疾病活动性和代谢,且与体重无关

Aimo Kannt, Paulus Wohlfart, Andreas Nygaard Madsen, Sanne Skovgård Veidal, Michael Feigh, Dieter Schmoll

Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis

Elafibranor 和利拉鲁肽在非酒精性脂肪性肝炎小鼠模型中不同程度地改善肝脏健康和代谢

Nikolaos Perakakis, Konstantinos Stefanakis, Michael Feigh, Sanne S Veidal, Christos S Mantzoros

Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH

恩格列净可改善非糖尿病肥胖小鼠模型(经活检证实为晚期非酒精性脂肪性肝炎)的代谢和肝脏结局。

Perakakis, Nikolaos; Chrysafi, Pavlina; Feigh, Michael; Veidal, Sanne Skovgard; Mantzoros, Christos S

TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan

TAK1 抑制剂单独使用或与美法仑联合使用对多发性骨髓瘤细胞均有细胞毒性

Erling Håland, Ingrid Nyhus Moen, Elias Veidal, Hanne Hella, Kristine Misund, Tobias S Slørdahl, Kristian K Starheim

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis

GLP-1R/GcgR 双激动剂 Cotadutide 通过调节线粒体功能和脂肪生成来缓解 NASH 和肝纤维化

Michelle L Boland #, Rhianna C Laker #, Karly Mather, Arkadiusz Nawrocki, Stephanie Oldham, Brandon B Boland, Hilary Lewis, James Conway, Jacqueline Naylor, Silvia Guionaud, Michael Feigh, Sanne S Veidal, Louise Lantier, Owen P McGuinness, Joseph Grimsby, Cristina M Rondinone, Lutz Jermutus, Martin

The Selective Peroxisome Proliferator-Activated Receptor Gamma Modulator CHS-131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis

选择性过氧化物酶体增殖物激活受体γ调节剂CHS-131可改善肥胖和非酒精性脂肪性肝炎小鼠模型的肝脏组织病理学和代谢

Nikolaos Perakakis ,Aditya Joshi ,Natia Peradze ,Konstantinos Stefanakis ,Georgia Li ,Michael Feigh ,Sanne Skovgard Veidal ,Glenn Rosen ,Michael Fleming ,Christos S Mantzoros

Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative

二十碳五烯酸衍生物二十碳丁酸酯可双重靶向肝纤维化和动脉粥样硬化。

Stokman, Geurt; van den Hoek, Anita M; Denker Thorbekk, Ditte; Pieterman, Elsbet J; Skovgård Veidal, Sanne; Basta, Brittany; Iruarrizaga-Lejarreta, Marta; van der Hoorn, José W; Verschuren, Lars; Berbée, Jimmy F P; Rensen, Patrick C N; Skjaeret, Tore; Alonso, Cristina; Feigh, Michael; Kastelein, John J P; Friedman, Scott L; Princen, Hans M G; Fraser, David A